Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Perseus ProteomicsTSE:4882 +2.56%56 Quick Ratio is 24.48 as of Mar. 2026, which is 8% above its 10-year median of 22.61. GuruFocus rates TSE:4882 with a GF Score™ of 56/100 and a GF Value™ of 円439.72 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 999 Drug Manufacturers companies, Perseus Proteomics ranks better than 98.3% on this metric.
Perseus Proteomics has a quick ratio of 24.48. It generally indicates good short-term financial strength.
The historical rank and industry rank for Perseus Proteomics's Quick Ratio or its related term are showing as below:
TSE:4882'
s Quick Ratio Range Over the Past 10 Years
Min: 8.64 Med: 22.61 Max: 61.83
Current: 24.48
During the past 9 years, Perseus Proteomics's highest Quick Ratio was 61.83. The lowest was 8.64. And the median was 22.61.
TSE:4882's Quick Ratio is ranked better than 98.3% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.45
vs TSE:4882: 24.48
Perseus Proteomics (TSE:4882) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Perseus Proteomics Quick Ratio Related Terms
Perseus Proteomics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Perseus Proteomics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4882 vs LLY, JNJ, ABBV: Quick Ratio Comparison
For the Drug Manufacturers - General subindustry, Perseus Proteomics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Perseus Proteomics Quick Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Perseus Proteomics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Perseus Proteomics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Perseus Proteomics's Quick Ratio for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Perseus Proteomics (TSE:4882) has a Quick Ratio of 24.48 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Perseus Proteomics and its competitors. This is near median its historical median of 22.61. Over the past decade, Perseus Proteomics' Quick Ratio has ranged from 8.64 to 61.83. According to the industry distribution chart, Perseus Proteomics ranks #17 out of 999 companies in the Drug Manufacturers industry, placing it in the top 1.7%.
Is Perseus Proteomics' Quick Ratio too high?
Perseus Proteomics' current Quick Ratio of 24.48 is near median its 10-year median of 22.61. Over the past 10 years, this metric has ranged from a low of 8.64 to a high of 61.83. The Drug Manufacturers industry median Quick Ratio is 1.45. Perseus Proteomics' value of 24.48 is 1588.3% above this industry median. Based on the distribution chart, Perseus Proteomics ranks #17 out of 999 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Perseus Proteomics has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Perseus Proteomics' Quick Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Perseus Proteomics ranks #17 out of 999 companies for Quick Ratio. This places Perseus Proteomics in the top 2% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 1.45. Perseus Proteomics' value of 24.48 is 1588.3% above this benchmark. Historically, Perseus Proteomics' own Quick Ratio has ranged from 8.64 to 61.83 over the past decade. While the company's 10-year median is 22.61 vs. the industry median of 1.45, Perseus Proteomics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Drug Manufacturers company?
The median Quick Ratio among Drug Manufacturers companies is 1.45, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Perseus Proteomics's current Quick Ratio of 24.48 is 1588.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Perseus Proteomics and its competitors. For the Drug Manufacturers industry, the median Quick Ratio is 1.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Perseus Proteomics's current Quick Ratio is 24.48, which is near median its own 10-year median of 22.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perseus Proteomics stock overvalued right now?
Based on GuruFocus' analysis, Perseus Proteomics (TSE:4882) is currently considered Significantly Undervalued. The stock's GF Value™ is 円439.72, compared to a current price of 円160.00 — trading 63.6% below its estimated fair value. The current Quick Ratio is 24.48, which is near median its 10-year median of 22.61 and 1588.3% above the Drug Manufacturers industry median of 1.45. Perseus Proteomics' overall GF Score™ is 56/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Perseus Proteomics (TSE:4882), the current Quick Ratio is 24.48 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Perseus Proteomics (TSE:4882) Overvalued in 2026?
Based on GuruFocus' analysis, Perseus Proteomics stock appears to be undervalued.
The current stock price of 円160.00 is trading 63.6% below its estimated GF Value™ of 円439.72.
GuruFocus considers Perseus Proteomics to be Significantly Undervalued.
Key valuation signals for TSE:4882:
Quick Ratio: 24.48 (near median its 10-year median of 22.61)
GF Value™: 円439.72 vs. price of 円160.00 (63.6% below fair value)
Industry Position: 1588.3% above the Drug Manufacturers median (#17 of 999)
No single metric tells the full story. See the TSE:4882 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Perseus Proteomics Inc is engaged in the research and development, manufacture, and sales of pharmaceuticals. It provides antibody-based therapeutics and diagnostic drugs to cure cancer and other diseases. The Company operates in a single segment, the pharmaceutical business.
56GF Score
Get the complete analysis for TSE:4882
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4882 has been successfully added to your 
